Insider Transactions in Q1 2025 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2025
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,698
-0.13%
|
$15,282
$9.0 P/Share
|
|
Mar 24
2025
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,698
+0.13%
|
$10,188
$6.32 P/Share
|
|
Mar 14
2025
|
Kyle Piskel Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.91%
|
$15,000
$6.32 P/Share
|
|
Mar 13
2025
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
36,291
-70.22%
|
$254,037
$7.19 P/Share
|
|
Mar 12
2025
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
53,000
-43.2%
|
$371,000
$7.59 P/Share
|
|
Mar 10
2025
|
Peter M Neupert Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.26%
|
$70,000
$7.05 P/Share
|
|
Mar 10
2025
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.56%
|
$200,000
$4.07 P/Share
|
|
Mar 06
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
102,218
-3.34%
|
$715,526
$7.64 P/Share
|
|
Mar 06
2025
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
15,664
-23.26%
|
$109,648
$7.94 P/Share
|
|
Mar 05
2025
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,320
-1.24%
|
$61,920
$6.98 P/Share
|
|
Mar 05
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
44,665
-5.14%
|
$267,990
$6.99 P/Share
|
|
Mar 05
2025
|
Susan Bobulsky Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
26,023
-6.97%
|
$156,138
$6.98 P/Share
|
|
Mar 05
2025
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
20,875
-2.99%
|
$125,250
$6.99 P/Share
|
|
Mar 05
2025
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
247,117
+7.47%
|
-
|
|
Mar 05
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
117,351
-2.02%
|
$704,106
$6.99 P/Share
|
|
Mar 05
2025
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
96,656
-3.57%
|
$579,936
$6.99 P/Share
|
|
Mar 05
2025
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
59,505
-4.69%
|
$357,030
$6.99 P/Share
|
|
Mar 04
2025
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+30.92%
|
-
|
|
Mar 04
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
109,973
+20.09%
|
-
|
|
Mar 04
2025
|
Susan Bobulsky Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
119,971
+24.32%
|
-
|
|
Mar 04
2025
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,976
+22.04%
|
-
|
|
Mar 04
2025
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,394
+11.15%
|
-
|
|
Mar 04
2025
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,394
+7.69%
|
-
|
|
Mar 04
2025
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,394
+17.49%
|
-
|
|
Mar 04
2025
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,394
+18.09%
|
-
|
|
Mar 04
2025
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
355,000
+10.8%
|
-
|
|
Mar 04
2025
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
355,000
+20.51%
|
-
|
|
Mar 04
2025
|
Julie Rubinstein President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+21.27%
|
-
|
|
Mar 04
2025
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,394
+18.6%
|
-
|
|
Feb 20
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
99,107
-3.7%
|
$792,856
$8.44 P/Share
|
|
Feb 20
2025
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
99,107
+3.57%
|
$594,642
$6.32 P/Share
|
|
Feb 19
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
186,080
-6.74%
|
$1,488,640
$8.46 P/Share
|
|
Feb 19
2025
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
186,080
+6.31%
|
$1,116,480
$6.32 P/Share
|
|
Feb 18
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
211,160
-7.57%
|
$1,689,280
$8.5 P/Share
|
|
Feb 18
2025
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
211,160
+7.04%
|
$1,266,960
$6.32 P/Share
|
|
Feb 14
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
158,921
-5.81%
|
$1,271,368
$8.46 P/Share
|
|
Feb 14
2025
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
158,921
+5.49%
|
$953,526
$6.32 P/Share
|
|
Feb 13
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
100,287
-3.75%
|
$802,296
$8.44 P/Share
|
|
Feb 13
2025
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
100,287
+3.61%
|
$601,722
$6.32 P/Share
|